PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma

Hepatic and circulating levels of PCSK9 in morbidly obese patients: relation with severity of liver steatosis

(2020) Maria R. Emma et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma

(2020) Silvano Fasolato et al.   Journal of Clinical Medicine

PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT

(2018) Wen-Kai Shi et al.   Cell Death & Disease

The Rho GTPase Rnd1 inhibits epithelial–mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target

(2018) Cheng-Dong Qin et al.   Cell Death & Disease

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis

(2017) Xiao-Xiao He et al.   European Journal of Internal Medicine

Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment

(2017) Robert Dufour et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Network analyses identify liver‐specific targets for treating liver diseases

(2017) Sunjae Lee et al.   Molecular Systems Biology

PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways

(2017) Xiaohui Xu et al.   Experimental and Therapeutic Medicine

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

(2016) Steven E. Nissen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2

(2016) De-Ning Ma et al.   Journal of Hematology & Oncology

Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans

(2016) Lei Li et al.   JOURNAL OF HEPATOLOGY

A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition

(2016) Jian’an Bai et al.   Oncotarget

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver

(2015) Xiaowei Sun et al.   NEOPLASIA

Variable effects of gender and Western diet on lipid and glucose homeostasis in aged PCSK9-deficient C57BL/6 mice 性别与西方饮食对CSK9基因缺陷的PC57BL/6老龄小鼠的脂质以及葡萄糖内稳态的不同影响

(2014) Majambu Mbikay et al.   Journal of Diabetes

Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype

(2013) Zuhier Awan et al.   CANADIAN JOURNAL OF CARDIOLOGY

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study

(2012) Robert P Giugliano et al.   LANCET

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

(2012) Jan Budczies et al.   PLoS One

Hepatitis C virus entry: beyond receptors

(2012) Luke W. Meredith et al.   REVIEWS IN MEDICAL VIROLOGY

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

(2011) Paola Lo Surdo et al.   EMBO REPORTS

PCSK9 impedes hepatitis C virus infectionin vitroand modulates liver CD81 expression

(2009) Patrick Labonté et al.   HEPATOLOGY

Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor

(2009) Sha Huang et al.   JOURNAL OF LIPID RESEARCH

Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

(2008) Ahmed Zaid et al.   HEPATOLOGY